PubRank

Patricia Landis

Author PubWeight™ 59.08‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 2006 6.02
2 Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 2011 5.27
3 Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 2010 4.17
4 Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 2007 3.14
5 Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst 2006 2.96
6 Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol 2002 2.68
7 Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance. J Urol 2013 2.66
8 Serial prostate biopsies are associated with an increased risk of erectile dysfunction in men with prostate cancer on active surveillance. J Urol 2009 2.18
9 Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab 2006 2.17
10 Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. J Urol 2009 2.17
11 Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer. J Urol 2012 1.80
12 PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the Baltimore Longitudinal Study of Aging. Eur Urol 2008 1.78
13 ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program. Urology 2011 1.71
14 Prostate specific antigen testing among the elderly--when to stop? J Urol 2009 1.62
15 Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol Biomarkers Prev 2005 1.55
16 Multiparametric magnetic resonance imaging findings in men with low-risk prostate cancer followed using active surveillance. BJU Int 2013 1.55
17 Low prostate-specific antigen and no Gleason score upgrade despite more extensive cancer during active surveillance predicts insignificant prostate cancer at radical prostatectomy. Urology 2012 1.54
18 Risk stratification of men choosing surveillance for low risk prostate cancer. J Urol 2010 1.47
19 Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer. BJU Int 2012 1.44
20 Prostate-specific antigen velocity risk count assessment: a new concept for detection of life-threatening prostate cancer during window of curability. Urology 2007 1.36
21 Expanded criteria to identify men eligible for active surveillance of low risk prostate cancer at Johns Hopkins: a preliminary analysis. J Urol 2013 1.30
22 Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer. Clin Cancer Res 2009 1.26
23 Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer? J Urol 2003 1.03
24 Prostate specific antigen predicts the long-term risk of prostate enlargement: results from the Baltimore Longitudinal Study of Aging. J Urol 2002 0.97
25 Serum prostate-specific antigen (PSA) concentration is positively associated with rate of disease reclassification on subsequent active surveillance prostate biopsy in men with low PSA density. BJU Int 2013 0.96
26 Effect of intra-observer variation in prostate volume measurement on prostate-specific antigen density calculations among prostate cancer active surveillance participants. BJU Int 2011 0.92
27 DNA content in the diagnostic biopsy for benign-adjacent and cancer-tissue areas predicts the need for treatment in men with T1c prostate cancer undergoing surveillance in an expectant management programme. BJU Int 2009 0.90
28 Using nuclear morphometry to predict the need for treatment among men with low grade, low stage prostate cancer enrolled in a program of expectant management with curative intent. Prostate 2008 0.86
29 Prostate-specific antigen and all-cause mortality: results from the Baltimore Longitudinal Study On Aging. J Natl Cancer Inst 2004 0.82
30 Repeat prostate biopsies predict location of index cancer in an active surveillance cohort. BJU Int 2011 0.80
31 PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml. Urology 2002 0.79
32 The Optimal Application of Prostate-Specific Antigen (PSA) Velocity to Predict High-Risk Disease. Eur Urol 2008 0.78
33 Can a baseline prostate specific antigen level identify men who will have lower urinary tract symptoms later in life? J Urol 2005 0.75